MétaCan
Menu
Back to cohort
Record W4236635032 · doi:10.1093/ecco-jcc/jjw019.702

P583. Real-world use and effectiveness of golimumab for ulcerative colitis in Canada

2016· article· en· W4236635032 on OpenAlexaffabout
Mohamed Bejaoui, Fabienne Charbit‐Henrion, Cécilia Landman, Harry Sokol, Anne Bourrier, Isabelle Nion–Larmurier, Jacques Cosnes, Laurent Beaugerie, Philippe Seksik, Brian Bressler, Martin Williamson, Fernando Camacho, Bernie D. Sattin, A. Hillary Steinhart

Bibliographic record

VenueJournal of Crohn s and Colitis · 2016
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicInflammatory Bowel Disease
Canadian institutionsUniversity of TorontoUniversity of British Columbia
Fundersnot available
KeywordsGolimumabUlcerative colitisMedicineInternal medicineInfliximabDisease

Abstract

fetched live from OpenAlex

Background: Measurement of trough levels and detection of antidrug antibodies have gained importance in the management of loss of response (LOR) in inflammatory bowel diseases (IBD) patients under anti-tumour necrosis factor (TNF)-alpha therapy.Nevertheless, their role in quiescent IBD is still debated.The aim of this study was to assess predictive value of infliximab trough levels in quiescent IBD under maintenance infliximab therapy.Methods: We conducted a single-centre prospective study enrolling all consecutive IBD patients in clinical remission under maintenance infliximab therapy between January and March 2011.Clinical remission was defined as CDAI < 150 in Crohn's disease (CD) and as a simplified Mayo score < 3 in ulcerative colitis (UC).Trough levels of Infliximab in serum (TLI) and antibodies to Infliximab (ATI) were assessed just before infliximab infusion.Loss of response (LOR) was pragmatically defined by the occurrence of either a therapy optimisation, a switch to another biologic, an intestinal surgery, or an IBD complication.Patients were prospectively monitored between January 2011 and March 2014.C-reactive protein (CRP) levels were collected, and CDAI or simplified Mayo score were calculated at each infliximab infusion.Univariate and multivariate analysis using Cox model were performed to identify predictive factors of LOR.Results: In total, 66 patients with quiescent IBD (29 CD and 37 UC) were included.Average age was 35.5 years [17-86] and sex ratio M / F was 0.94.At baseline, 32 patients had TLI < 3 µg/ ml (IFX-group), and 34 had TLI > 3 µg/ml (IFX+ group).The 2 groups were similar regarding age at IBD onset, gender distribution, smoker status, and IBD clinical features according to the Montreal Classification and concomitant immunosuppressive therapy.ATI were found in 5 (15.1%) patients from the IFX-group but in none of the IFX+ group.LOR was significantly higher in IFX-group when compared with the IFX+ (51.7% vs 22.2%; p = 0.02).Rates of complications, therapy optimisation and surgery requirements were similar in the 2 groups.Multivariate analysis showed that 2 factors were associated with LOR within 3 years: TLI < 3 µg/ ml at baseline (OR = 3.67; IC 95% [1.39-9.69];p = 0.009) and perianal lesions at baseline (OR = 3; IC 95% [1.20-2.46];p = 0.018).Conclusions: This study suggests that low trough levels of infliximab (< 3 µg / ml) in patients with IBD in clinical remission under infliximab maintenance therapy are predictive to a LOR in the medium term.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.003
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.047
Threshold uncertainty score0.150

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.003
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0010.002
Science and technology studies0.0010.000
Scholarly communication0.0010.000
Open science0.0010.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0040.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.008
GPT teacher head0.238
Teacher spread0.231 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2016
Admission routes2
Has abstractyes

Explore more

Same venueJournal of Crohn s and ColitisSame topicInflammatory Bowel DiseaseFrench-language works237,207